Naperville, IL -- (SBWire) -- 04/29/2014 --Reportstack, provider of premium market research reports announces the addition of Colazal & Giazo (Ulcerative Colitis) - Forecast and Market Analysis to 2022 market report to its offering
Colazal & Giazo (Ulcerative Colitis) - Forecast and Market Analysis to 2022

Summary

During the forecast period from 2012-2022, the growth of the UC market will be driven largely by the entry of Johnson & Johnsons (J&Js) Simponi and Takedas Entyvio, which will lead to an increase in the overall number of patients being treated with biologics in the US, 5EU, Japan, and Canada. Another key event affecting the UC market is the anticipated launch of biosimilars, given that the patent expiry of the UC blockbusters, Remicade and Humira are set to expire in the US in 2018 and 2016, respectively.

Colazal is an aminosalicylate prodrug. This means that its active ingredient, balsalazide disodium, contains an azo bond that can only be processed by bacterial azo reductases in the colon. Following its metabolism by the colonic commensal bacteria, mesalamine is released into and is restricted to the colon area, preventing the active ingredient from being systemically absorbed. Giazo is an aminosalicylate prodrug. This means that its active ingredient, balsalazide disodium, contains an azo bond that can only be processed by bacterial azo reductases in the colon. Following metabolism by the colonic commensal bacteria, mesalamine is released into and is restricted to the colon area, preventing the active ingredient from being systemically absorbed.

Scope

- Overview of Ulcerative Colitis, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape._x000D_
- Detailed information on Colazal & Giazo including product description, safety and efficacy profiles as well as a SWOT analysis._x000D_
- Sales forecast for Colazal & Giazo for the top three countries from 2012 to 2022._x000D_
- Sales information covered for the US, Italy, and the UK.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return_x000D_
- Stay ahead of the competition by understanding the changing competitive landscape for Ulcerative Colitis_x000D_
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential_x000D_
- Make more informed business decisions from insightful and in-depth analysis of Colazal & Giazo performance _x000D_
- Obtain sales forecast for Colazal & Giazo from 2012-2022 in the top three countries (the US, Italy, and the UK.)

To view the table of contents for this market research report please visit
http://www.reportstack.com/product/153370/colazal-giazo-ulcerative-colitis-forecast-and-market-analysis-to-2022.html
Contact:
Roger Campbell
contactus@reportstack.com
Naperville
Illinois
United States
Ph: 888-789-6604
###